Considerable variation in the rate of adoption of infliximab and etanercept biosimilars is observed within England, Scotland and Wales.

Implementation of biosimilars into clinical practice is facilitated by gain share agreements, regional and local leadership, and sharing of best practices from early adopters.

Over time, there is convergence towards high biosimilar market shares across England, Scotland and Wales.